We offer our registered users tailored information, free online courses and exclusive content.
Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?
... or you lost your password?
In the Latin-American nations type 2 Diabetes is a growing problem, mainly due to the spread of a western life-style characterized by a hypercaloric diet, sedentary behaviour, and finally obesity. Its management, including the related complications and comorbidities, is a challenge for the local healthcare systems and professionals, particularly because of the lack of standardised guidelines, limited medical services and limited public finance. Also, in many countries in this region, thyroid disorders are very common, mostly due to iodine deficiency but also to genetic factors, leading to nodular goiter and immune dysfunctions. Hypo- and hyperthyroidism, thyroid nodules and ultimately thyroid cancers are frequent challenges for local physicians and healthcare systems, requiring tailored medical intervention and standards of care using international guidelines. EXCEMED is focusing its efforts on organising a dedicated educational conference for health care professionals involved in the management of diabetes and thyroid disorders, particularly in regions at highest risk. The aims of this conference are to review the most significant achievements of research in the fields, and to share best practice for the clinical management of such diseases.
After attending the live educational conference, participants will have up-to-date knowledge about the latest in research and clinical management of diabetes and thyroid disorders, and will be able to:
EXCEMED (www.excemed.org) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The Advances and challenges in the management of diabetes and thyroid disorders conference to be held in Sao Paulo, Brazil on 10-11 October 2014, is designated for a maximum of 9 (nine) hours of European CME credits (ECMEC). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. EACCME® credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, please contact the AMA.
EXCEMED adheres to the principles of the Good CME Practice Group (gCMEp).
Friday, 10 October 2014
Session I Managing the emergency of diabetes today
Chair: Marcos Tambascia (Brazil)
09.00 L1: “Diabesity” in Latin-America: from predisposition to prevention
Walmir Coutinho (Brazil)
09.30 L2: Comparing international to local guidelines for diabetes management
Luiz Turatti (Brazil)
10.00 L3: Management of pre-diabetes: role of pharmacological therapy
Monica Manrique (Chile)
Session II Treating diabetes and improving the outcomes
Chair: Marcos Tambascia (Brazil)
11.00 L4: Efficacy and safety of metformin as first-line therapy in diabetes
Marilia de Brito Gomes (Brazil)
11.30 L5Lowering glucose levels: from oral therapy to insulin therapy
Marcos Tambascia (Brazil)
12.00 L6: How to improve poor adherence to treatment in diabetes
Monica Manrique (Chile)
12.30 RT1: Managing hyperglycemia in the old and young people
Marilia de Brito Gomes (Brazil)
Marcos Tambascia (Brazil)
Session III From iodine deficit to thyroid autoimmune diseases
Chair: Hans Graf (Brazil)
14.00 L7: Iodine deficiency and its consequences in Latin-America today
Eduardo A. Pretell (Peru)
14.30 L8: Graves disease and its complications: etiology and therapy
Ana Luiza Maia (Brazil)
15.00 L9: Managing hypothyroidism according to international and local guidelines
Mario Vaisman (Brazil)
Session IV Interactive workshops with clinical case presentations (16.00-18.00)
W1: Gestational diabetes management: from diagnosis to medical therapy
Rosângela Réa (Brazil)
W2: Thyroid disorders in pregnancy: when to use thyroid hormone therapy
Gabriela Brenta (Argentina)
Saturday, 11 October 2014
Session V Complications and comorbidities of diabetes
Chair: Marcos Tambascia (Brazil)
09.00 L10: Diabetic nephropathy: moving from pathogenesis to therapy
Louis Henrique Canani (Brazil)
09.30 L11: Unravelling the neglected problem of diabetic neuropathy
Hermelinda Pedrosa (Brazil)
10.00 L12: Cardiovascular disease and diabetes: more than an association
Sergio A. Dib (Brazil)
Session VI Managing thyroid nodules and thyroid cancers
Chair: Hans Graf (Brazil)
11.00 L13: Multinodular goiter: from hormone therapy to radioiodine therapy
Hans Graf (Brazil)
11.30 L14: Novel non-invasive treatment of benign thyroid nodules
Enrico Papini (Italy)
12.00 L15: International guidelines for managing differentiated thyroid cancers
Erivelto Volpi (Brazil)
12.30 RT2: Managing subclinical hypothyroidismChair: Gabriela Brenta (Argentina)
Hans Graf (Brazil); Enrico Papini (Italy); Mario Vaisman (Brazil); Erivelto Volpi (Brazil)
EXCEMED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME ® ) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of EXCEMED. All presentations represent solely the independent views of the presenters/authors.
The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:
Gabriela Brenta Declared receipt of honoraria and consultation fees from Merck.
Marilia de Brito Gomes Declared no potential conflict of interest.
Walmir Coutinho Declared Consulting with Novo Nordisk, Germed, Abbott Nutrition, Weight Watchers International, Aché, Janssen, Pathway Genomics. He declared to in the boards of Janssen, Novo Nordisk, Aché, Abbott Nutrition, Merck Serono and Astra Zeneca.
Sergio A. Dib Declared no potential conflict of interest.
Hans Graf Declared no potential conflict of interest.
Ana Luiza Maia Declared receipt of grants from CNPq, FAPERGS, NIH, FIPE. She is consultant or advisor for AstraZeneca and Bayer and principal investigator for AstraZeneca and Exelixis.
Enrico Papini Declared receipt of grants and contracts: IBSA, Esaote-Elesta, Novartis.
Hermelinda Pedrosa Declared receipt of honoraria or consultation fees from Ely Lilly, Novartis, Merck Serono. She declared participation in a company sponsored speakers’ bureau: Sanofi Aventis.
Eduardo A. Pretell Declared no potential conflict of interest.
Rosângela Réa Declared no potential conflict of interest.
Marcos Tambascia Declared receipt of grants and research supports from MSD, NovoNordisk and receipt of honoraria or consultation fees from NovoNordisk, Sanofi, Takeda, Lilly, Boehringer-Ingelheim. He declared participation in a company sponsored speaker’s bureau: NovoNordisk, Sanofi, Boehringer- Ingelheim, Lilly.
Luiz Turatti Declared receipt of honoraria and consultation fees from Sanofi, Astra Zeneca, Merck. Novartis, Lilly. He declared to be member of a company advisory board, board of directors or other similar groups: Sanofi, Merck and Novartis.
Mario Vaisman Declared to be member of a company advisory board, board of directors or other similar groups: Sanofi.
Erivelto Volpi Declared no potential conflict of interest.
The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of 25 September 2014.
Jorge Gross
Monica Manrique
